CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
肿瘤免疫治疗：挑战与局限
英文原题：Cancer immunotherapy: Challenges and limitations.
查看英文原题
Cancer immunotherapy: Challenges and limitations.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
尽管癌症免疫治疗已在主流肿瘤学中占据中心地位，可诱导完全且持久的肿瘤消退，但仅有一部分接受治疗的患者产生应答，其他患者在初始应答后复发。不同肿瘤类型的应答不同，即使在有应答的癌症类型（热肿瘤）中，我们仍观察到无应答的肿瘤（冷肿瘤），提示存在耐药性。因此，内在或获得性耐药的发生是癌症免疫治疗领域的一大挑战。对免疫治疗（包括检查点抑制剂、CAR-T 细胞疗法、溶瘤病毒和重组细胞因子）的耐药，是由于癌细胞采用多种机制逃避免疫监视所致。
展开英文摘要原文
Although cancer immunotherapy has taken center stage in mainstream oncology inducing complete and long-lasting tumor regression, only a subset of patients receiving treatment respond and others relapse after an initial response. Different tumor types respond differently, and even in cancer types that respond (hot tumors), we still observe tumors that are unresponsive (cold tumors), suggesting the presence of resistance.
Hence, the development of intrinsic or acquired resistance is a big challenge for the cancer immunotherapy field. Resistance to immunotherapy, including checkpoint inhibitors, CAR-T cell therapy, oncolytic viruses, and recombinant cytokines arises due to cancer cells employing several mechanisms to evade immunosurveillance.
论文信息
- 作者
- Taefehshokr S、Parhizkar A、Hayati S、Mousapour M、Mahmoudpour A、Eleid L、Rahmanpour D、Fattahi S
- 单位
- Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: sinataefehshokr@gmail.com.Iran
- 文献类型
- 综述
- 期刊
- Pathology, research and practice2022 Jan
- 原文标识
- PubMed 34952426 · DOI 10.1016/j.prp.2021.153723